Ex-Neuralink president Max Hodak implants first vision chip in Stargardt patient

Max Hodak, the former president and co-founder of Neuralink, just crossed a milestone in a different corner of the neural interface world. His startup, Science Corporation, has implanted its vision-restoring chip in its first patient with Stargardt disease, a genetic condition that destroys central vision, often beginning in childhood or early adulthood. Hodak detailed the development on stage at TechCrunch Disrupt.

The chip, called PRIMA, is a photovoltaic retinal implant: a tiny device placed under the retina that converts light into electrical signals the brain can interpret. For Hodak, the Stargardt implant is a deliberate stepping stone. He framed the work as part of Science Corp's path toward a novel brain-computer interface (BCI), the same frontier he helped pioneer at Neuralink before leaving to found his own company.

The patient population makes this first implant especially significant. Stargardt disease is one of the most common inherited forms of macular degeneration in young people, and it has no cure and few treatment options. Historically, most retinal implant research has focused on retinitis pigmentosa, a different degenerative condition that strikes later in life. Stargardt typically manifests as central vision loss that worsens over time, and while it does not cause complete blindness, it can rob patients of the ability to read, drive, and recognize faces. This first Stargardt implant opens a new clinical front: if PRIMA restores meaningful vision in this patient, it would validate the technology in a younger, harder-to-treat population.

The technology is a study in miniaturization. PRIMA works in tandem with augmented reality glasses that project near-infrared light patterns onto the retina. The chip converts that light into electrical stimulation, bypassing the photoreceptor cells that Stargardt disease kills. Because the chip is photovoltaic, it is powered by the light itself: no wires, no batteries, no cables crossing the skin. That design simplicity is a major advantage over earlier retinal implants that required bulky external hardware and complex surgical procedures.

Hodak's BCI framing is the strategic tell. Vision is the beachhead: the eye is the most accessible part of the nervous system, the regulatory pathway for ophthalmic devices is well-trodden, and the patient need is urgent and visible. A successful retinal implant proves the company can build, surgically implant, and clinically validate a neural interface in a living human, which is the hardest part of any BCI program. Everything after that is incremental.

The field's history is littered with cautionary tales. Retinal implants have promised more than they delivered for decades, and the commercial graveyard includes companies that burned through hundreds of millions of dollars before failing. The lesson from those failures is that clinical efficacy alone is not enough: the device must be manufacturable, implantable by ordinary surgeons, and reimbursable by payers. The regulatory bar is instructive as well: ophthalmic devices have a defined approval pathway, but regulators want evidence of functional benefit, not just anatomical success. Science Corp will need to show that PRIMA patients can actually see better, not merely that the chip is safely implanted.

For executives watching the neurotech race, this first-patient milestone is a de-risking event. It moves Science Corp from preclinical promise to clinical proof-of-concept, and it puts competitive pressure on Neuralink and other BCI players pursuing different routes to the same destination. The race to the brain is no longer a single-company story; it is a portfolio of approaches, and the vision-first strategy just gained a credible data point.

The strategic lesson for founders and operators is about sequencing. Hodak chose a tractable clinical problem with a clear regulatory path, proved the implant works in humans, and only then pointed toward the more ambitious BCI vision. That is a playbook any deep-tech founder can borrow: find the beachhead application that de-risks the core technology, win the first patients, and let the long-term vision follow. The first Stargardt implant is one small chip in one patient's eye, but it is also a signal that the brain-computer interface era is arriving through the back door.